DCM
INO icon

Delpha Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Delpha Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-326
Closed -$16K – 639
2017
Q4 		$16K Buy
+326
New +$20.2K 0.02% 876

Other funds holding INO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $15.9B AUM 53.4% 1-Year Est. Return

Delpha Capital Management's INO Position: Q1 2018 in Review

Delpha Capital Management sold out of Inovio Pharmaceuticals (INO) in Q1 2018, closing a stake of 326 shares — an estimated $16K sold.

Delpha Capital Management first reported a position in INO in Q4 2017 and held it in 1 quarter. The position peaked at $16K in Q4 2017. 126 funds tracked by Wall St. Rank hold INO as of Q1 2018.

  • Delpha Capital Management reported no remaining Inovio Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 326 Inovio Pharmaceuticals shares in Q1 2018, an estimated $16K.
  • Delpha Capital Management first reported a position in Inovio Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Inovio Pharmaceuticals position peaked at $16K in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.